April 27, 2022
JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
April 25, 2022
Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.
April 25, 2022
Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.
April 25, 2022
Based on an interim analysis of a randomized phase 2 trial, use of topical ruxolitinib showed reduced body surface area of chronic graft-versus-host disease.
April 25, 2022
Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.
April 24, 2022
In patients with relapsed/refractory large B-cell lymphoma, the chimeric antigen receptor T-cell agent, lisocabtagene maraleucel demonstrated durable responses.
April 24, 2022
The majority of patients treated in a phase 1 trial of belimumab used as chronic graft-vs-host-disease prophylaxis showed no evidence of the disease after 20 months of follow-up.
April 24, 2022
In a phase 2 trial, rates of steroid-refractory chronic graft versus host disease and prednisone use following treatment with abatacept after stem cell transplant were reduced.
April 24, 2022
In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.
April 24, 2022
According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.